

## 4th EAS Pediatric Familial Hypercholesterolemia symposium

Saturday 30<sup>th</sup> of May 2020, Geneva, Switzerland

Organized by: Dr Nathalie Brun and Dr Diana Ballhausen

### 10.00-10.05 Welcome and dedication to Gaby Hanauer-Mader - Steve Humphries

### 10.05 – 11.30 Topic 1 - Safety and efficacy of lipid lowering treatments – Chair Nathalie Brun and Albert Wiegman

1. How big is the risk of fetal anomalies due to statin use in pregnancy? Meeike Kusters (Holland)
2. FH and Pregnancy – results of a survey - Kirsten Holven (Norway)
3. Safety and efficacy of use of evolocumab in children – Albert Wiegman (Holland)
4. Liver transplantation in HOZ FH – Is this only a last resort treatment? Jeanine Roeters van Lennep (Holland)
5. Pediatric HoFH trial with lomitapide and recent data – Luis Masana (Spain)
6. Differences in Lipid-lowering treatment of children across Europe – results from the IAS Children's FH Register – Uma Ramaswami

### Coffee

### 12.00- 13.00 Topic 2 - Update on FH Genetics – Chair Michal Vrablik and Andre Miserez

1. Genetics of FH in Switzerland - Andre Miserez (Switzerland).
2. New genes causing FH – update from the UK 100,000 genome project – Antoine Rimbert (France)
3. How to handle the findings of a VUS in an index case – *In silico* predictions, AMCG criteria and *in vitro* Assays – Mafalda Bourbon (Portugal) and Tomas Freiburger (Czech Republic)
4. High triglycerides in children – how high before we get worried? - Michal Vrablik (Czech Republic)

Lunch 13.00-14.00

### 14.00-16.00 Topic 3 - Universal Screening for FH in childhood - Chair Steve Humphries and Sam Gidding

1. What do Patients value most about a diagnosis of FH and how this can be used as part of evidence of clinical utility - Jules Payne (UK)
2. The Russian Experience – Marat Ezhov (Russia)
3. The Bavaria Project – Wolfgang Koenig (Germany)
4. The Berlin and Mecklenburg experience - Elizabeth Steinhagen-Thiessen (Germany)
5. Early Exposure to high LDL-C and future CHD risk – trajectory analysis - Andrew Moran (USA)
6. The Australian experience - Gerald Watts (Australia)
7. Are statin treated FH children at higher risk of T2D? – Justin Zachariah (USA)
8. How concerned should we be about high Lp(a) in children as a future CHD risk factor? Martin Bogsrud (Norway)

### Discussion